The board of directors of CSPC Pharmaceutical Group Limited announced that the mRNA Respiratory Syncytial Virus (RSV) Vaccine (SYS6016) developed by the Group, has obtained approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China. The Product consists of mRNA molecules encoding the prefusion conformation of the full-length RSV fusion glycoprotein (F-protein), which is encapsulated within lipid nanoparticles. It is indicated for the prevention of lower respiratory tract diseases caused by RSV infections.

Preclinical studies demonstrated that the Product translates into the prefusion conformation F-protein in vivo and induces high titers of long-lasting neutralising antibodies. It exhibits good protection against both RSV-A and RSV-B subtype viral strains and has a good safety profile. RSV can cause respiratory infections in people of all ages, especially children, the elderly, and adults with immunodeficiency or underlying health conditions.

These groups are more likely to experience severe infections, respiratory sequelae, and even death, thereby resulting in a significant burden on human health and society. Currently, there is no vaccine available for RSV infections in China, and the Product is at the forefront in the research and development progress in China. The Group will endeavour to advance the clinical research of the Product and strive to market the Product as soon as possible so as to create value for the society and shareholders.